Publications by authors named "T Labella Caballero"
Hereditary angioedema (HAE) has been recognized for almost 150 years. The newest form of HAE, where C1 inhibitor levels are normal (HAE-nC1INH), was first described in 2000. Over the last two decades, new types of apparent non-mast cell-mediated angioedema with normal quantity and activity of C1INH have been described, in some cases with proven genetic pathogenic variants that co-segregate with angioedema expression within families.
View Article and Find Full Text PDFAdvent of oral medications for the treatment of hereditary angioedema.
Clin Transl Allergy
September 2024
Article Synopsis
- Hereditary angioedema (HAE) is a rare condition that causes sudden swelling in the body, which can be dangerous, and needs special care.
- * There are currently two main ways to manage HAE: having quick access to treatments when episodes happen and preventing attacks with medications.
- * New oral medications for HAE are being developed and tested, which might make it easier for patients to treat their condition without having to use needles.
Background: Hereditary angioedema (HAE) is characterized by debilitating attacks of tissue swelling in various locations. While guidelines recommend the importance of early on-demand treatment, recent data indicate that many patients delay or do not treat their attacks.
Objective: This survey aimed to investigate patient behavior and evaluate the key factors that drive on-demand treatment decision-making, as reported by those living with HAE.